Medico Remedies pays ₹56,640 fine for non-compliance

Medico Remedies Limited paid penalties totaling ₹56,640 to each of the National Stock Exchange of India Limited (NSE) and BSE Limited for alleged non-compliance with Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company settled the fines on May 25, 2026, after receiving notices from both exchanges on May 20, 2026. The non-compliance pertained to the period from January 1, 2026, to February 17, 2026.

Details of the Violation

The notices issued by the exchanges cited a failure to adhere to disclosure timelines under Regulation 6(1). The NSE notice referenced letter number NSE/LIST-SOP/COMB/FINES/0573, while the BSE notice was sent via email number SOP-CReview/QTR-Mar-26. The company attributed the delay to an inadvertent miss in disclosing the intimation within the prescribed timelines.

Financial Impact and Compliance Status

Particulars	Details
Authority	NSE and BSE
Penalty Amount	₹56,640 (inclusive of GST) per exchange
Date of Notice	May 20, 2026
Date of Payment	May 25, 2026
Compliance Status	Compliant since February 18, 2026

Medico Remedies stated that the payment of fines has no material impact on its financials, operations, or other activities. The company confirmed that it became compliant with Regulation 6(1) effective February 18, 2026. Management has assured stakeholders that measures are in place to prevent such lapses in the future.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.85%	-7.03%	+7.38%	-14.63%	-13.28%	+88.10%

Medico Remedies Limited has reported its audited standalone financial results for the financial year ended March 31, 2026. The company's board approved the results during a meeting held on May 21, 2026. M/s. Shah Shroff & Associates, the statutory auditors, issued an audit report with an unmodified opinion on the financial statements.

For the full year, the company recorded a net profit of ₹1,311.52 lakh, an increase from ₹1,009.32 lakh in the previous year. Revenue from operations grew to ₹20,637.73 lakh compared to ₹15,094.06 lakh in FY25. Total income for the year stood at ₹21,231.08 lakh, up from ₹15,363.00 lakh in the prior year.

Financial Performance

The company's total expenses for FY26 amounted to ₹19,425.12 lakh, higher than the ₹14,012.63 lakh reported in the previous year. Profit before tax for the year was ₹1,805.96 lakh, compared to ₹1,350.37 lakh in FY25. The basic and diluted earnings per share (EPS) for the year were reported at ₹1.58, up from ₹1.22 in the corresponding period last year.

Quarterly Results

For the quarter ended March 31, 2026, medico remedies reported a net profit of ₹585.66 lakh. Revenue from operations for the quarter stood at ₹5,680.77 lakh, while total income was ₹5,968.16 lakh. Total expenses for the quarter were ₹5,136.23 lakh, resulting in a profit before tax of ₹831.92 lakh.

Financial Position

The company's total assets as of March 31, 2026, stood at ₹15,340.33 lakh, an increase from ₹11,979.93 lakh in the previous year. Total equity rose to ₹7,547.45 lakh from ₹6,246.89 lakh. Current assets increased significantly to ₹12,891.76 lakh, driven by higher trade receivables and inventories.

Metric	FY26 (₹ in lakhs)	FY25 (₹ in lakhs)
Revenue from Operations	20,637.73	15,094.06
Total Income	21,231.08	15,363.00
Total Expenses	19,425.12	14,012.63
Net Profit	1,311.52	1,009.32
EPS (Basic)	1.58	1.22

Cash Flow and Segment Reporting

Net cash flow from operating activities for the year was ₹587.42 lakh, compared to ₹489.21 lakh in the previous year. The company reported that it operates as a single operating segment. Geographical sales data for the quarter ended March 31, 2026, showed sales outside India at ₹5,364.29 lakh, while domestic sales were ₹274.48 lakh.